Background:Brain metastases commonly occur in patients with metastatic melanoma and are associated with a poor prognosis. Only a few chemotherapeutic agents have been shown to be potentially active. Resistance to chemotherapy is one of the main limitations to treatment. A key mechanism of resistance is O6-methylguanine-DNA methyltransferase (MGMT). The methylation of its promotor could inhibit the activity of this enzyme; consequently, it is very important to evaluate the methylation status of all available specimens.Case Report:We report the case of a long-surviving patient in whom combination treatment with an alkylating agent inhibiting MGMT, such as temozolomide, was useful in clinical control of the disease.
Titolo: | The Role of O6-Methylguanine-DNA Methyltransferase in a Long-Surviving Metastatic Melanoma |
Autori: | |
Data di pubblicazione: | 2014 |
Rivista: | |
Abstract: | Background:Brain metastases commonly occur in patients with metastatic melanoma and are associated with a poor prognosis. Only a few chemotherapeutic agents have been shown to be potentially active. Resistance to chemotherapy is one of the main limitations to treatment. A key mechanism of resistance is O6-methylguanine-DNA methyltransferase (MGMT). The methylation of its promotor could inhibit the activity of this enzyme; consequently, it is very important to evaluate the methylation status of all available specimens.Case Report:We report the case of a long-surviving patient in whom combination treatment with an alkylating agent inhibiting MGMT, such as temozolomide, was useful in clinical control of the disease. |
Handle: | http://hdl.handle.net/11368/2740499 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.2310/7750.2013.13045 |
URL: | http://www.ncbi.nlm.nih.gov/pubmed/24377476 |
Appare nelle tipologie: | 1.1 Articolo in Rivista |